Therapy Areas: Diabetes
Senseonics Prices Public Offering of Common Stock
19 July 2019 - - US-based medical technology company Senseonics Holdings, Inc. (NYSE American: SENS) has priced a registered underwritten public offering of 22,727,273 shares of its common stock at a ...
Parvus Therapeutics Names Rienhoff as Chairman
17 July 2019 - - Canadian biopharmaceutical company Parvus Therapeutics has appointed Hugh Young Rienhoff, Jr., M.D., as chairman of the board, Charles A. Johnson, M.D., to the board of directors, and...
AstraZeneca provides update on decision by US FDA for Farxiga in type-1 diabetes
16 July 2019 - AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Monday the issue by the US Food and Drug Administration (FDA) of a complete response letter rega...
Gilead Sciences, Renown Institute for Health Innovation Team to Advance Understanding of Nonalcoholic Steatohepatitis
15 July 2019 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) and US-based healthcare network the Renown Institute for Health Innovation have forged a strategic collaboratio...
Metavant and Poxel Tout Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4
12 July 2019 - - Switzerland-based clinical-stage biopharmaceutical company Metavant Sciences and France-based Poxel SA (Euronext: POXEL FR0012432516) have received positive topline results ...
Immunovia to present findings of IMMray PanCan-d optimisation study at PancreasFest 2019
12 July 2019 - Immunovia AB (STO:IMMNOV), a manufacturer of healthcare devices, reported on Thursday that additional, more detailed data from the optimisation study of IMMray PanCan-d will be presente...
Related Headlines

Martin Edwards Elected as Chair of KalVista Pharmaceuticals Board of Directors

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis R and D Pipeline with New First-in-Class Compound from Yuhan Corp.

Bicycle Therapeutics Touts Positive Topline Results from Oxurion's Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

Biocorp enters talks with Sanofi to use Mallya connected device with Sanofi's diabetes care platform

AgaMatrix and WaveForm Technologies conclude USD56m financing agreement

AstraZeneca reports recommendation of EU CHMP for Forxiga's marketing authorisation to include DECLARE-TIMI 58 CV outcomes data

Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery

vTv Therapeutics Starts Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

US FDA grants Boehringer Ingelheim and Eli Lilly fast track designation for Empagliflozin

The University of Virginia's Center for Diabetes Technology Licenses Klue's Meal Detection Technology to Advance Diabetes Treatment

US FDA expands use of Symdeko to include patients ages six years and older for cystic fibrosis

Xeris Pharmaceuticals Touts Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

SERAXIS Inc enters into diabetes research agreement with North Carolina research hospital

LUNGevity strengthens leadership team to accelerate progress for lung cancer patients

Novo Nordisk wins US FDA approval for Victoza to treat type 2 diabetes in children and adolescents aged 10-17 years